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Models for prediction of allogeneic hematopoietic stem transplantation (HSCT) related mor-
tality partially account for transplant risk. Improving predictive accuracy requires understat-
ing of prediction limiting factors, such as the statistical methodology used, number and
quality of features collected, or simply the population size. Using an in-silico approach (i.e.,
iterative computerized simulations), based on machine learning (ML) algorithms, we set out
to analyze these factors. A cohort of 25,923 adult acute leukemia patients from the Euro-
pean Society for Blood and Marrow Transplantation (EBMT) registry was analyzed. Predic-
tive objective was non-relapse mortality (NRM) 100 days following HSCT. Thousands of
prediction models were developed under varying conditions: increasing sample size, spe-
cific subpopulations and an increasing number of variables, which were selected and
ranked by separate feature selection algorithms. Depending on the algorithm, predictive
performance plateaued on a population size of 6,611–8,814 patients, reaching a maximal
area under the receiver operator characteristic curve (AUC) of 0.67. AUCs’ of models
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developed on specific subpopulation ranged from 0.59 to 0.67 for patients in second com-
plete remission and receiving reduced intensity conditioning, respectively. Only 3–5 vari-
ables were necessary to achieve near maximal AUCs. The top 3 ranking variables, shared
by all algorithms were disease stage, donor type, and conditioning regimen. Our findings
empirically demonstrate that with regards to NRM prediction, few variables “carry the
weight” and that traditional HSCT data has been “worn out”. “Breaking through” the predic-
tive boundaries will likely require additional types of inputs.
Introduction
Allogeneic hematopoietic stem transplantation (HSCT) is a potentially curative procedure for
selected patients with hematological malignancies. Transplant associated morbidity and mor-
tality remains substantial, making the decision of whom, how and when to transplant, of great
importance [1].
The European Group for Blood and Marrow Transplantation (EBMT) score, initially devel-
oped for prediction of allogeneic HSCT outcomes in chronic myeloid leukemia, and later vali-
dated for other diagnoses, has pioneered the field of prognostic modeling in HSCT [2, 3]. Since
its release, almost two decades ago, additional scores have also been developed. These have
been validated, but do not fully account for transplantation risk in acute leukemia [4–9].
Performance limiting factors of HSCT prediction models might be attributed to inherent
procedural uncertainty, the statistical methodology used, or the number and quality of features
collected. Using an in-silico approach (i.e., iterative computerized simulations), based on
machine learning (ML) algorithms, we set out to explore these factors in order to improve
future acute leukemia HSCT outcome prediction models.
ML is a field in artificial intelligence. The underlying paradigm does not start with a pre-
defined model; rather it lets the data create the model by detecting underlying patterns. Thus,
this approach avoids pre-assumptions regarding model types and variable interactions, and
may offer additional knowledge, which has eluded detection by standard statistical methods.
ML algorithms, have been applied in various "big data" scenarios such as financial markets,
complex physical systems, marketing, advertising, robotics, meteorology, biology and more.
They are tools in the data mining approach for knowledge discovery in large datasets [10, 11].
Recently, we have developed the EBMT- Alternating Decision Tree (ADT) ML based predic-
tion model for mortality at 100 days following allogeneic HSCT in acute leukemia [9, 12].
Hence, demonstrating feasibility of the data mining approach in HSCT.
Methods
Study population
This was a retrospective, data mining, supervised learning study, based on data reported to the
Acute Leukemia Working Party (ALWP) registry of the EBMT. The EBMT is a voluntary
group of more than 500 centers, required to report all consecutive HSCT and follow-ups annu-
ally in a standardized manner. The study was approved by the ALWP board. Written informed
consent was given by participants for their clinical records to be used in EBMT retrospective
studies.
Inclusion criteria encompassed first allogeneic transplants from HLA matched sibling and
unrelated donors (> = 8/10), performed from 2005 to 2013, using peripheral blood stem cells
In-Silico Predictive Modeling of HSCTMortality
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or bone marrow as cell source, on adults (age> = 18 years) diagnosed with de-novo acute leu-
kemia. Haploidentical and cord blood transplants were not included.
A total of 26,266 patients from 326 European centers were initially analyzed. Patients lost
from follow-up before day 100 post HSCT were discarded from analysis (n = 343, 1.3%). Twenty
two variables describing recipient, donor, and procedural characteristics were considered.Vari-
ables were defined according to EBMT criteria (Table 1 and Appendix A in S1 File) [13].
Study objectives
Study objectives included development of multiple prediction models for NRM 100 days post
allogeneic HSCT, while estimating effects of the algorithm type, population size, specific sub-
populations and number of variable incorporated, on the models' predictive performance. Day
100 NRM was defined as death without previous relapse/progression before day 100.
Study design
Prediction models for day 100 NRM were developed using six ML algorithms (WEKA v. 3-7-
11, New-Zealand). Through an in-silico approach, algorithms were iteratively exposed to an
increasing population size, varying sub-populations, or an increasing number of ranked vari-
ables, selected by a separate feature selection algorithm (Fig 1). For each iteration, a prediction
model was trained and tested through 10 fold cross-validation. This process was repeated 5
times, each time randomly sampling the experimental dataset (see below). Performance was
evaluated according to the area under receiver operator characteristic curve (AUC) [14, 15].
Tuning of the algorithms parameters (Table A in S1 File) and the feature selection process,
explained below, were conducted on an optimization dataset (n = 3,888, 15%), whereas the
development of the various models of day 100 NRM prediction were done on the experimental
dataset (n = 22,035, 85%). Samples were randomly allocated to each dataset from the original
dataset.
Machine learning Algorithms
Six popular, supervised classification ML algorithms were selected (Appendix B in S1 File).
Naïve bayse (NB), alternating decision trees (ADT) and logistic regression (LR) produce mod-
els with interpretable structures, whereas multilayer perceptron (MLP), random forest (RF)
and AdaBoost are "black box" models, where the function connecting the predictor variables
with response is opaque to the user [16–22].
Feature selection
Feature selection is the process of ranking variables and identifying irrelevant and redundant
information. The reduction of dimensionality presents a number of benefits, such as enabling
algorithms to operate faster and more effectively, improving classification accuracy, improving
data visualization, and enhancing understanding of the derived classification models [23].
Using a classifier based feature selection algorithm, which was applied on the optimization
dataset for each of the 6 previously described ML classification algorithms, variables were
ranked according to their importance for prediction of day 100 NRM (Appendix C in S1 File).
Results
Patient characteristics
Characteristics of 25,923 analyzed patients are listed in Table 1. The majority had Acute Mye-
loid Leukemia (AML) (71.8%), were in first complete remission (CR1) (62.5%) and received
In-Silico Predictive Modeling of HSCTMortality
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Table 1. Patient Characteristics. Interquartile range (IQR), Body mass index (BMI), Recipient (R), Donor (D), Cytomegalovirus (CMV), Acute lymphoblastic
leukemia (ALL), Total body irradiation (TBI), Graft versus host disease (GVHD), Antithymocyte globulin (ATG), Peripheral blood (PB), Bone marrow (BM)
Value N Missing, n
Median year (IQR) 2009 (2007–2011) 25923 0
Median recipient age (IQR) 45 (33–56) 25923 0
Median BMI (IQR) 24 (22–27) 9350 16573
Median days between diagnosis and HSCT (IQR) 191 (138–363) 25914 9
Median donor's age (IQR) 38.8 (29–48) 10027 15896
Recipient gender 25872 51
Male 14228 (55.0%)
Female 11644 (45.0%)
Recipient CMV serostatus 22855 3068
- 7788 (34.1%)
+ 15067 (65.9%)
Karnofsky at transplant 24369 1554
> = 80 22966 (94.2%)
<80 1403 (5.8%)









Cytogenetics risk 13430 12493
Standard 10080 (75.1%)
Poor 3350 (24.9%)




Previous autograft 25923 0
- 25235 (97.3%)
+ 688 (2.7%)
Donor gender 25357 566
Male 15712 (62.0%)
Female 9645 (38.0%)
Donor CMV serostatus 22726 3197
- 10927 (48.1%)
+ 11799 (51.9%)
D-R sex combination 25318 605
Male D to male R 9153 (36.2%)
Female D to female R 4863 (19.2%)
Male D to female R 6528 (25.8%)
Female D to male R 4774 (18.9%)
D-R CMV serostatus combination 22395 3528
D-CMV–/R-CMV– 5572 (24.9%)
(Continued)
In-Silico Predictive Modeling of HSCTMortality
PLOS ONE | DOI:10.1371/journal.pone.0150637 March 4, 2016 4 / 14
myeloablative conditioning (MAC) (66.2%). Grafts from matched sibling donors were used in
47.6% of patients. Graft source was mainly peripheral blood (84.1%). NRM and overall mortal-
ity prevalence at day 100, were 9.2% (n = 2,387) and 12.7% (n = 3,280) respectively. Whereas
9.8% (n = 2,539) of patients relapsed before 100 days. They were consequently considered as
no NRM at day100. The parameter optimization and experimental datasets were similar in
terms of baseline characteristics (Table B in S1 File).
Sample size effect on prediction
Day 100 NRM prediction models were developed with 6 ML algorithms on an expanding
patient population (110–22,035 patients) sampled from the experimental dataset. When mod-
els were developed on all available patients, AUCs ranged from 0.64 for the MLP algorithm to
0.67 for the LR and AdaBoost algorithms (Fig 2 and Table C in S1 File). Depending on the algo-
rithm, predictive performance plateaued on a sample size of 6,611–8,814 patients. Samples
Table 1. (Continued)
Value N Missing, n
D-CMV+/R-CMV–or D-CMV–/R-CMV+ 8917 (39.8%)
D-CMV+/R-CMV+ 7906 (35.3%)
Donor type 25923 0
HLA matched unrelated donor 13585 (52.4%)
HLA identical sibling 12338 (47.6%)




Source of stem cells 25923 0
BM 4109 (15.9%)







GVHD prevention 23228 2695
Ex-vivo T cell depletion 800 (3.4%)
In-vivo T cell depletion 9825 (42.3%)
No T cell depletion 12603 (54.3%)
Relapse at day 100 25923 0
- 23384 (90.2%)
+ 2539 (9.8%)
Non relapse related mortality at day 100 25923 0
- 23536 (90.8%)
+ 2387 (9.2%)
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Fig 1. In-silico predictivemodeling- experimental design. The original dataset was randomly split into an
optimization and experimental datasets. The former was used for tuning of machine learning algorithms and
feature selection.A. Several experiments were run on the experimental dataset, testing the effects of
population size, specific subpopulations and number of variables included on predictive performance. B. A
detailed explanation of the increasing population size experiment displayed in panel A. Patients were
randomly sampled from the experimental dataset, creating samples with an expending size, which were later
introduced to six machine learning algorithms. For each sample a prediction model for day 100 NRMwas
developed, and performance was measured through the area under the receiver operating curve (AUC).
Models were trained and tested with 10 fold cross validation. The sampling process was repeated 5 times. C.
For estimation of variable importance (ranked variables experiment in panel A) and the number of variables
necessary for optimal prediction of day 100 NRM, we ran a feature selection algorithm on the optimization
In-Silico Predictive Modeling of HSCTMortality
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consisting of 551 patients or less, demonstrated poor performance with AUCs ranging from
0.56–0.59.
Sub-population effect on prediction
Prediction models were developed for specific subsets of patients, and performance was com-
pared with models developed on the whole population (Table 2). Performance was significantly
lower for the various disease stage subpopulations (e.g., for CR2 AUC ranged from 0.55–0.59)
and for patients transplanted from HLA matched unrelated donors. Prediction models devel-
oped on the remaining subpopulations had similar performance to models developed using all
available patients.
set. Variables were ranked according to their predictive contribution to each algorithm. The next step involved
serial introduction of the variables, according to their importance to six machine learning algorithms which
were applied on the experimental dataset. In each iteration a prediction model for day 100 NRMwas trained
and test with 10 fold cross validation. For instance in the first iteration the top ranking variable was introduced,
in the second the top 2 variables and so on until all 23 variables were used. Performance was estimated
according to the AUC. Machine learning (ML), Algorithm (Alg).
doi:10.1371/journal.pone.0150637.g001
Fig 2. Predictive performance of day 100 NRM predictionmodels with increasing sample size. A gradually increasing sample from the experimental
dataset was introduced to 6 machine learning algorithms. Prediction models were developed for each incremental step and their discriminative performance
is plotted on the Y axis. Alternating decision tree (ADT), Logistic regression (LR), Multilayer perceptron (MLP), Naïve base (NB), Random forest (RF).
doi:10.1371/journal.pone.0150637.g002
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Variable importance
When the feature selection process was applied on the optimization set, disease stage, donor
type and conditioning were consistently the 3 top ranking variables across all day 100 NRM
prediction models (Fig 3). The mean variable rankings of time from diagnosis to transplant,
recipient age, and diagnosis were 4–6, respectively. However, standard deviation was consider-
ably high, as their importance varied between algorithms.
To assess the relationship between models' performance and the number of variables incor-
porated into them, the ranked variables were serially introduced to the 6 ML algorithms. The
algorithms were applied on the experimental dataset. Starting from the top ranking variables,
gradually adding variables with lower ranking, prediction models for day 100 NRM were itera-
tively constructed (Fig 1). The maximal predictive performance ranged from 0.65–0.67, with
LR and MLP achieving their optimal AUC with only 6 variables (Fig 4). When introduced with
the 3 top ranking variables all models achieved an AUC of 0.64.
Discussion
Eligibility of patients with acute leukemia for allogeneic HSCT is based on a risk benefit-assess-
ment of the relapse risk versus NRM risk [24]. Risk scores for transplant associated mortality
have been developed based on retrospective registry data. A large HSCT registry was explored,
while automatizing the prediction model development processes, creating thousands of mod-
els, depending on the questions asked. We show that for day 100 NRM prediction various
models, developed on the basis of 6 popular ML algorithms, reach approximately the same per-
formance. With data commonly collected, saturation of predictive performance requires very
few variables, but large datasets.
The nature of association between predictors and response, the data’s quality and
dimensionality (i.e., number of variables analyzed), and the number of events per outcome, all
affect the sample size necessary for generation of a robust and generalizable prediction model
Table 2. Predictive performance of day 100 NRM prediction models on varying subpopulations.
AdaBoost ADT LR MLP NB RF Average
performance
Sample Size AUC STDV AUC STDV AUC STDV AUC STDV AUC STDV AUC STDV AUC STDV
Full dataset 22035 0.67 0.02 0.66 0.02 0.67 0.02 0.63 0.01 0.65 0.02 0.66 0.02 0.66 0.01
Age<45 10820 0.66 0.03 0.65 0.03 0.66 0.03 0.64 0.02 0.65 0.03 0.66 0.03 0.65 0.01
Age> = 45 11215 0.66 0.03 0.65 0.03 0.66 0.03 0.64 0.02 0.65 0.03 0.65 0.03 0.65 0.01
ALL 6214 0.65 0.04 0.64 0.04 0.66 0.04 0.64 0.02 0.64 0.03 0.65 0.03 0.65 0.01
AML 15821 0.67 0.02 0.66 0.03 0.67 0.02 0.65 0.02 0.65 0.02 0.66 0.02 0.66 0.01
CR1 13787 0.63 0.03* 0.61 0.03* 0.64 0.03* 0.63 0.02 0.61 0.03* 0.62 0.03* 0.62 0.01
CR2 4165 0.58 0.05* 0.55 0.04* 0.59 0.05* 0.59 0.03* 0.58 0.05* 0.58 0.05* 0.58 0.01
Advanced 4083 0.62 0.04* 0.61 0.04v 0.61 0.04v 0.59 0.03v 0.6 0.03* 0.61 0.04* 0.61 0.01
MAC 14754 0.66 0.02 0.65 0.02 0.66 0.02 0.63 0.02 0.65 0.02 0.66 0.02 0.65 0.01
RIC 7703 0.67 0.03 0.66 0.03 0.67 0.03 0.66 0.02 0.65 0.03 0.66 0.03 0.66 0.01
MRD 10458 0.65 0.03 0.64 0.03 0.66 0.03 0.65 0.03 0.65 0.03 0.65 0.03 0.65 0.01
MUD 11577 0.64 0.02* 0.63 0.03* 0.64 0.03* 0.62 0.02 0.62 0.03* 0.63 0.02* 0.63 0.01
* p-value <0.05 (t-test), Performance of reach model was compared with the performance of the model developed on the full experimental dataset, with
the designated algorithm. Standard deviation (STDV), Alternating decision tree (ADT), Logistic regression (LR), Multilayer perceptron (MLP), Naïve base
(NB), Random forest (RF), HLA matched related donor (MRD), HLA matched unrelated donor (MUD).
doi:10.1371/journal.pone.0150637.t002
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[15]. Hence, predetermination of the sample size is a matter of empirical testing, rather than a
standardized calculation. Using repetitive computerized simulations, we demonstrate that with
marginal differences between algorithms, approximately 6,000 patients were needed to achieve
maximal or near-maximal predictive performance. Defining a strict cutoff for modeling studies
would be erroneous, as the data’s features differ between cohorts. However, a rather solid
assumption based on the presented results on “real world” data, would be the need to include
thousands of patients when aiming to develop and validate similar modeling problems.
Iterative development of prediction models for specific subpopulation has drawn attention
to the different disease stage groups. Performance was lowest for the CR2 group, with an AUC
ranging from 0.53–0.58. Low performance, but to lesser extent, was also noted for the other dis-
ease stage groups. Disease stage is highly predictive of day 100 NRM. Thus, it is not surprising
that when disease stage was excluded from the pool of variables considered for prediction, per-
formance declined, as it is highly informative.
Prospects for cure are higher for patients in CR1 compared to other disease stages. Hence,
estimation of NRM risk is of special interest in this group, as non-transplant alternatives exist
[25–27]. Versluis et al., have addressed such a population receiving reduced intensity condi-
tioning. When looked upon separately, the Hematopoietic Cell Transplantation-Specific
Comorbidity Index (HCT-CI) and EBMT score were not predictive of NRM, corroborating the
Fig 3. Mean variable ranking of day 100 NRM predictionmodels. Variable importance were extracted using a feature selection algorithm for 6 machine
learning prediction models of day 100 NRM. The circle marks the mean ranking of each variable and the bars describe 2 standard deviations. Disease stage
(Ds_Stage); Time from transplant to diagnosis (Time_dx); Diagnosis (Dx); Body mass index (BMI); Donor (D); Recipient (R); Previos autograft (2nd_tx); # of
HLA mismatches (#HLA_miss); Graft versus host disease prophylaxis (GVHD_prox); Total body irradiation (TBI);
doi:10.1371/journal.pone.0150637.g003
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challenge we encountered. A new score, based on integrated feature of the comorbidity index
and EBMT score, was constructed achieving an AUC of 0.68 [8].
It should be noted that most algorithms reached an AUC of 0.65 using only 3–5 variables.
Adding more variables led to a modest improvement, which translates to marginal clinical sig-
nificance. The top 3 ranking variables, shared by all algorithms were disease stage, donor type,
and conditioning. Transplanters will not be surprised by these determinants, which have been
validated repeatedly [28, 29]. Predictive weight attributed to other features varied considerably
between models, leading at best to modest increment in predictive accuracy. Traditional HSCT
prognostic studies, rely on a collection of variables similar to the one presented. Thus, effective
prediction of individualized NRM is unlikely to substantially improve. Incorporation of the
HCT-CI score holds promise. However, even when applied separately or in combination with
other features, the comorbidity index reaches a maximal AUC of 0.7 [4, 7, 8, 30–32]. In other
words, contemporary prognostic models are suitable for risk stratification rather than outcome
prediction. The discovery of additional prognostic markers, the incorporation of electronic
medical records to routine clinical use, and the addition of biological and genetic data to infor-
mation gathered on leukemia patients, offers great opportunities for model improvement
[33, 34].
Fig 4. Predictive performance of day 100 NRM predictionmodels on a cumulative ranked variable list. Alternating decision tree (ADT); Logistic
regression (LR); Multilayer perceptron (MLP); Naïve base (NB); Random forest (RF);
doi:10.1371/journal.pone.0150637.g004
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Mortality following transplantation is likely the result of a complex network of interactions
and non-linear associations. Hence, the Occam's razor concept, where the simplest solution is
the best solution, might not hold for prediction of transplantation outcomes. Exploiting the
abundance of data now available on transplant patients, could potentially improve prediction
models’ applicability. Novel modeling techniques such as ML [35, 36], enabling non-parsimo-
nious incorporation of a high number of variables, are warranted. These methods could poten-
tially improve accuracy, but interpretability might be lost.
The EBMT-ADT prediction model marked the entrance of the data mining methodology
into HSCT prognostic research [9, 22]. The aim of the ADT study was development of a pre-
diction model for overall mortality at 100 days following allogeneic HSCT in acute leukemia
patients. Though using a data mining methodology, the perspective of the current study was
not prediction per-se, but rather an analysis of the predictive modeling process and its bound-
aries, while focusing on NRM at day 100 as the objective. Thousands of prediction models,
with varying algorithms, were developed and evaluated in order to discover elements that
could improve future models. The in-silico experimental system allowed us to dissect the con-
ditions under which the models were developed and the corresponding performance. Thus,
providing methodological and clinical insights regarding sample size, modeling technique, and
variable importance.
The study carries several limitations. First, it is a retrospective analysis susceptible to data
selection and measurement biases. However, the registry analyzed reflects real world data,
hence conveying contemporary practice. Second, a few variables suffered from a large amount
of missing values. That being said, ML algorithms allow prediction of the outcome of interest
without strong assumptions regarding the distribution and missingness, In addition, we show
that when discarding variables with more than 15% missing values, prediction does not
improve (Table D in S1 File). Third, we focus on short term data- day 100 NRM, rather than
long term mortality. We believe that the high rate of day 100 NRM (9.2%) makes it a valid
objective. Moreover, prediction of long term outcomes might be expected to give lower perfor-
mance, as more parameters come into play. Hence, the concepts presented should be applicable
to modeling distant outcomes. Fourth, we relate to prediction of day 100 NRM as a simple clas-
sification task, disregarding the time to event effect. However, given the large sample size, dis-
regarding censored data (1.3%) is unlikely to have impact on performance.
Conclusion
The in-silico approach is a novel experimental system utilizing machine learning algorithms,
for empirical estimation of prediction boundaries in HSCT. Several clinical and methodological
lessons have been learned by the suggested approach. Large registry studies, involving thou-
sands of patients are necessary for development of robust prediction models, as performance of
different algorithms converged when sampling more than 6,000 patients. In addition, an
exhaustive search for variable importance, reveal that few variables "carry the weight" with
regard to predictive influence. Potential bias of the presented approach include: data quality
issues and selection of a short term rather than a long term outcome. Overall, it appears that
when using traditional HSCT data, a point of predictive saturation has been reached. Improv-
ing performance will likely require additional types of input like genetic, clonal and biologic
factors.
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